Modeling Ketosis-Prone Diabetes Remission Via Diverse Mechanisms of Glucotoxicity

Part of paid clinical trials in Atlanta, Georgia.

Sponsor
Emory University
Study ID
NCT06699810
Phase
PHASE4
Status
Recruiting
Apply to this trial

Conditions

  • Ketosis Prone Diabetes

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Continuous Glucose Monitoring — DEVICE
    After insulin discontinuation participants continue wearing their CGMs, for a total of 3 months.
  • Insulin — DRUG
    Participants will receive standard-of-care insulin treatment. Insulin dosing will be adjusted based on CGM glucose readings.

Study Details

The goal of this study is to quantify day-to-day changes in blood glucose during treatment towards remission in ketosis-prone diabetes (KPDM) and describe them using a mathematical model of KPDM pathogenesis and remission.

Key Dates

Start date
Jan 23, 2025
Status verified
May 2026
Primary completion
Jan 31, 2027
Completion
Jan 31, 2027

Study Design

Enrollment
12 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: Continuous Glucose Monitoring with Adjusted Insulin Doses
    Patients with ketosis-prone diabetes will wear a continuous glucose monitor (CGM) from the time of hospital discharge until insulin discontinuation. Insulin doses will be adjusted based on CGM glucose readings.

Primary Outcome Measure

Quantify Changes in Blood Glucose [ Time Frame: Up to 3 months ]

Central Contacts

Locations (2)

FacilityCityStateZIPSite coordinators
Emory University Hospital MidtownAtlantaGeorgia30308-
Grady Health SystemAtlantaGeorgia30303-

Find similar trials in Atlanta, GA

By research site
Emory University Hospital Midtown· Atlanta, GAGrady Health System· Atlanta, GA

Related Studies